title: [First-line bevacizumab in ovarian cancer].
abstract: Based on encouraging Phase II data, two randomized phase III trials (GOG218 and ICON7) aimed at showing a progression-free survival (PFS) benefit of bevacizumab combined with first-line paclitaxel and carboplatin, followed by maintenance bevacizumab, in ovarian cancer. The median PFS increased to four and two months, respectively, as compared to chemotherapy alone. However, these two trials left important questions like proper patient selection, optimal dose level and length of maintenance phase, unanswered. Neither do we know if the quite modest progression-free survival benefit will translate into an overall survival benefit. Consequently, first-line bevacizumab in ovarian cancer cannot at present be recommended.
authors.affiliation: TAYS:n naistentautien ja synnytysten vastuualue.
authors.forename: Johanna
authors.initials: J
authors.lastname: Mäenpää
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel